GSEP
CORT icon

Golden State Equity Partners’s Corcept Therapeutics CORT Stock Holding History

Golden State Equity Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$322 – 608
2026
Q1 		$322 Buy
+8
New +$299 ﹤0.01% 1925

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's CORT Position: Q2 2026 in Review

Golden State Equity Partners sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 8 shares — an estimated $322 sold.

Golden State Equity Partners first reported a position in CORT in Q1 2026 and held it in 1 quarter. The position peaked at $322 in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Golden State Equity Partners reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 8 Corcept Therapeutics shares in Q2 2026, an estimated $322.
  • Golden State Equity Partners first reported a position in Corcept Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Corcept Therapeutics position peaked at $322 in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.